<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01580046</url>
  </required_header>
  <id_info>
    <org_study_id>XNK201201</org_study_id>
    <nct_id>NCT01580046</nct_id>
  </id_info>
  <brief_title>Renal Toxicity of Iodixanol and Iopromide in Patients With Renal Dysfunction</brief_title>
  <acronym>RIPE</acronym>
  <official_title>Renal Toxicity of Iodixanol and Iopromide in Patients With Renal Dysfunction—a Multicentre, Single Blind, Randomized Controlled, Prospective Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yong Huo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University First Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare renal toxicity of Iodixanol and Iopromide in patients
      with renal dysfunction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed to compare renal toxicity of Iodixanol and Iopromide after coronary
      angiography or percutaneous coronary intervention (PCI) in patient with Chronic Kidney
      Disease, considering original renal function and adequate hydration. The risk of varying
      degree of renal impairment, changes of serum Cys C level will also be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>to evaluate the change in Glomerular Filtration Rate levels by Estimated Glomerular Filtration Rate</measure>
    <time_frame>days 3 and 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>In each group(Iodixanol group and Iopromide group), the proportion of patients exhibiting an increases of serum creatinine in different range(&lt;10%,10%~25%, and ≥25%), comparing with baseline level.</measure>
    <time_frame>days 3 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hemodialysis</measure>
    <time_frame>days 3 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Cystatin C level from baseline</measure>
    <time_frame>days 1 and 3</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Kidney Failure, Chronic</condition>
  <arm_group>
    <arm_group_label>Iodixanol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>iopromide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>iodixanol</intervention_name>
    <description>coronary angiography, 32gI/100ml, 40～60 ml once injection
left ventricular, aortic root and selective coronary angiography, 32gI/100ml, 30～60 ml once injection</description>
    <arm_group_label>Iodixanol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>iopromide</intervention_name>
    <description>coronary angiography, 370mgI/ml(0.769gIopromide/ml),5～8 ml once injection</description>
    <arm_group_label>iopromide</arm_group_label>
    <other_name>Ultravist</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provides written Informed Consent and is willing to comply with protocol requirements

          -  Is referred for cardiac angiography, with or without PCI

          -  Has a documented predose serum creatinine level of 1.5～3.5 mg/dl for men and 1.3～3.0
             mg/dl for women

          -  Serum creatinine levels of twice tests conform with the baseline criteria, and the
             difference of twice serum creatinine tests is not more than 30%(first test: within 3
             month,prior to enrollment; second test: at enrollment)

        Exclusion Criteria:

          -  Has a history of hypersensitivity to iodine-containing compounds

          -  Has end-stage renal disease

          -  Has kidney transplantation

          -  Has creatinine clearance rates &gt;60 ml/min in last 3 months

          -  Has acute coronary syndrome with heart failure(above class II in accordance with
             Killip or class III in accordance with the classification of the New York Heart
             Association (NYHA)) and shock

          -  Patients with cancer

          -  Has diabetes with serious complications, other kidney organs

          -  Patients with serious blood system disease

          -  Heart failure [class III~Ⅳ in accordance with the classification of the New York Heart
             Association (NYHA) and (or) pulmonary edema]

          -  Patients with hepatic insufficiency[3 times as ALT and (or) AST normal reference value
             limit]

          -  Has received an iodinated contrast agent within 14 days prior to the administration of
             the study agent

          -  Is scheduled to receive an iodinated contrast agent within 7 days after administration
             of the study agent

          -  Has acute renal failure or end-stage renal disease requiring dialysis in the past 3
             months

          -  Use of 3 days continuously nonsteroidal anti-inflammatory drugs within 1 week of the
             procedure

          -  Patients with hypotension [(SBP&lt;80 mmHg for over 1h and needing Medication or
             intraaortic balloon counterpulsation(IABP) ]

          -  Uncontrolled condition of hyperthyroidism

          -  pregnancy or lactation

          -  Is planned to receive the drugs without permission in this protocol

          -  Participating in another intervention research study in last 3 months

          -  legally incapacitated or limitations

          -  Any other conditions not suitable to be enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhaoping Liu, MD</last_name>
    <phone>86-10-83575727</phone>
    <email>dr_liuzhp@yahoo.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Anhui Provincial Hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ji Yan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kefu Feng, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yong Huo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhaoping Liu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fujian Medical University Union Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Lianglong Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xingchun Zheng, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangdong Academy Of Medical Sciences Guangdong General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jiyan Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yong Liu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital Of Guangxi Medical University</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lang Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiaocong Zeng, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The People's Hospital Of Hebei Province</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050051</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Xiaoyong Qi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tianhong Wang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henan Provincial People's Hospital</name>
      <address>
        <city>Luoyang</city>
        <state>Henan</state>
        <zip>450000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Chuanyu Gao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital To Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Xiaoshu Cheng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yanqing Wu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The People's Hospital Of Liaoning Province</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Zhanquan Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yongxin Wang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital Of Medical College Qingdao University</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Yi An, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hua Yu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanxi Cardiovascular Hospital</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030024</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Bao Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhongchao Wang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Weimin Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pla Navy General Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100048</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tianchang Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Central Hospital Of China Aerospace Corporation</name>
      <address>
        <city>Beijing</city>
        <zip>100049</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bin Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tao Qu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ying Shen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Yundai Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wei Dong, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sunying Hu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xinqiao Hospital, Third Military Medical University</name>
      <address>
        <city>Chongqing</city>
        <zip>400037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Lan Huang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jun Jin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yun He, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Renji Hospital ，Shanghai Jiao Tong University School Of Medicine</name>
      <address>
        <city>Shanghai</city>
        <zip>200001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ben He, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Chest Hospital Affiliated To Shanghai Jiaotong University</name>
      <address>
        <city>Shanghai</city>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Weiyi Fang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai First People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Shaowen Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2012</study_first_submitted>
  <study_first_submitted_qc>April 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2012</study_first_posted>
  <last_update_submitted>October 14, 2013</last_update_submitted>
  <last_update_submitted_qc>October 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Peking University First Hospital</investigator_affiliation>
    <investigator_full_name>Yong Huo</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Chronic Kidney Disease</keyword>
  <keyword>Coronary Angiography</keyword>
  <keyword>Contrast Media</keyword>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <keyword>Serum Creatinine</keyword>
  <keyword>Glomerular Filtration Rate</keyword>
  <keyword>Iodixanol</keyword>
  <keyword>Iopromide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

